These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31610949)

  • 1. The subcutaneous implantable cardioverter defibrillator in 2019 and beyond.
    van Dijk VF; Boersma LV
    Trends Cardiovasc Med; 2020 Aug; 30(6):378-384. PubMed ID: 31610949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device.
    Richardson TD; Hale L; Arteaga C; Xu M; Keebler M; Schlendorf K; Danter M; Shah A; Lindenfeld J; Ellis CR
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable Cardioverter Defibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients Under Thirty Years of Age.
    Chang PM; Powell BD; Jones PW; Carter N; Hayes DL; Saxon LA
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1183-1190. PubMed ID: 27334356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators.
    Ishida Y; Payne JE; Field ME; Gold MR
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1195-1201. PubMed ID: 32128931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation increases the risk of recurrent ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients.
    Rusnak J; Behnes M; Reiser L; Schupp T; Bollow A; Reichelt T; Borggrefe M; Ellguth D; Engelke N; El-Battrawy I; Ansari U; Barre M; Weidner K; Müller J; Barth C; Meininghaus DG; Akin M; Bertsch T; Taton G; Akin I
    Arch Cardiovasc Dis; 2021; 114(6-7):443-454. PubMed ID: 33967015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S; Aktas M; Mutluer FO; Guler TE; Dervis E; Argan O; Celikyurt U; Agir A; Vural A
    Acta Cardiol; 2019 Jun; 74(3):246-251. PubMed ID: 30058473
    [No Abstract]   [Full Text] [Related]  

  • 9. Repetitive shock therapy of subcutaneous implantable cardioverter defibrillators in a patient with idiopathic ventricular fibrillation: What is the mechanism?
    Hasegawa K; Miyazaki S; Ishikawa E; Mukai M; Aoyama D; Nodera M; Kaseno K; Tada H
    J Cardiovasc Electrophysiol; 2019 Oct; 30(10):2121-2124. PubMed ID: 31332856
    [No Abstract]   [Full Text] [Related]  

  • 10. SVT discrimination algorithms significantly reduce the rate of inappropriate therapy in the setting of modern-day delayed high-rate detection programming.
    Cheng A; Auricchio A; Schloss EJ; Kurita T; Sterns LD; Gerritse B; Brown ML; Fagan DH; Lexcen DR; Ellenbogen KA
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2877-2884. PubMed ID: 31646695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inappropriate cardioverter-defibrillator discharge continues to be a major problem in clinical practice.
    Jodko Ł; Kornacewicz-Jach Z; Kaźmierczak J; Rzeuski R; Zielonka J; Kaliszczak R; Safranow K
    Cardiol J; 2009; 16(5):432-9. PubMed ID: 19753522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ICD Therapies on Mortality in the OMNI Trial.
    Sun S; Johnson J; Degroot P; Brown ML; Obel O
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):192-9. PubMed ID: 26501695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arrhythmic episodes in patients implanted with a cardioverter-defibrillator - results from the Prospective Study on Predictive Quality with Preferencing PainFree ATP therapies (4P).
    Regoli F; Graf D; Schaer B; Duru F; Ammann P; Stefano LMDS; Naegli B; Burri H; Zbinden R; Krasniqi N; Fromer M;
    BMC Cardiovasc Disord; 2019 Jun; 19(1):146. PubMed ID: 31208342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).
    Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N
    Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With an Implantable Defibrillator.
    Strickberger SA; Canby R; Cooper J; Coppess M; Doshi R; John R; Connolly AT; Roberts G; Karst E; Daoud EG
    J Cardiovasc Electrophysiol; 2017 Apr; 28(4):416-422. PubMed ID: 28128491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.
    Ellenbogen KA; Koneru JN; Sharma PS; Deshpande S; Wan C; Szymkiewicz SJ
    JACC Clin Electrophysiol; 2017 Mar; 3(3):243-250. PubMed ID: 29759518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of medical reaction in management of inappropriate ventricular arrhythmia diagnosis: the inappropriate Therapy and HOme monitoRiNg (THORN) registry.
    Perrin T; Boveda S; Defaye P; Rosier A; Sadoul N; Bordachar P; Klug D; Ritter P; Belhameche M; Babuty D; Mansourati J; Lazarus A; Deharo JC
    Europace; 2019 Apr; 21(4):607-615. PubMed ID: 30605510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
    Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.